LENZ Therapeutics, Inc. (NASDAQ:LENZ)
| Market Cap | 95.83M-89.1% |
| Revenue (ttm) | 12.36M-29.4% |
| Net Income | -140.27M-138.2% |
| EPS | -4.49-112.8% |
| Shares Out | 31.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 2,257,731 |
| Open | 3.07 |
| Previous Close | 3.05 |
| Day's Range | 2.80 - 3.17 |
| 52-Week Range | 2.80 - 32.13 |
| Beta | 1.73 |
| Analysts | Buy |
| Price Target | 5.00(+63.93%) |
| Earnings Date | Mar 23, 2027 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About LENZ
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating LENZ in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 23, 2027Earnings report
Ask Barron about LENZ
$LENZ stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LENZ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LENZ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LENZ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LENZ Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| License revenue | $3.75M | 68.36% |
| Product sales, net | $1.74M | 31.64% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LENZ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LENZ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LENZ
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.15M |
| IWMiShares Russell 2000 ETF | $1.61M |
| VXFVanguard Extended Market ETF | $971.95K |
| FESMFidelity Enhanced Small Cap ETF | $774.25K |
| IBBiShares Biotechnology ETF | $649.68K |
| IWNiShares Russell 2000 Value ETF | $525.88K |
Estimated from each fund’s disclosed top holdings × AUM
LENZ Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LENZ’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 97 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 59.5